title: Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Tacchetti
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Pezzi
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Zamagni
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Pantani
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Serena
authors.initials: S
authors.lastname: Rocchi
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Beatrice Anna
authors.initials: BA
authors.lastname: Zannetti
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Katia
authors.initials: K
authors.lastname: Mancuso
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Rizzello
authors.affiliation: "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Italy michele.cavo@unibo.it.
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D000069286:Bortezomib / Q000627:therapeutic use; D018450:Disease Progression; D015870:Gene Expression; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood / Q000235:genetics*; D007075:Immunoglobulin M / Q000097:blood / Q000235:genetics*; D007136:Immunoglobulins / Q000097:blood / Q000235:genetics*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012008:Recurrence; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007147:Immunoglobulin Light Chains; D007075:Immunoglobulin M; D007136:Immunoglobulins; C009823:M-proteins (Myeloma); D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide